
Medicine trial meets primary endpoint in patients with chronic kidney disease
Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalization, and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That’s …
Read More